{"id":"NCT01014013","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)","officialTitle":"A Prospective, Multicenter, Partially-Blinded, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of INVANZ Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2009-11-16","resultsPosted":"2010-03-01","lastUpdate":"2017-03-22"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Tract Infection"],"interventions":[{"type":"DRUG","name":"ertapenem sodium (MK0826)","otherNames":["MK0826"]},{"type":"DRUG","name":"Comparator: ceftriaxone sodium","otherNames":[]}],"arms":[{"label":"ertapenem sodium (MK0826)","type":"EXPERIMENTAL"},{"label":"ceftriaxone sodium","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy of ertapenem sodium (Invanz) in treatment of complicated urinary tract infections with respect to the proportion of patients with a favorable microbiological response at 5-9 days post therapy.","primaryOutcome":{"measure":"Microbiological Response Assessment Profile","timeFrame":"5 to 9 days post-therapy","effectByArm":[{"arm":"MK0826","deltaMin":58,"sd":null},{"arm":"Ceftriaxone","deltaMin":63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22563210"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":132},"commonTop":["Diarrhea","Headache","Dyspepsia","Cough","Constipation"]}}